Synmosa Biopharma Past Earnings Performance
Past criteria checks 2/6
Synmosa Biopharma has been growing earnings at an average annual rate of 26.6%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 16.3% per year. Synmosa Biopharma's return on equity is 5%, and it has net margins of 11.6%.
Key information
26.6%
Earnings growth rate
24.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 16.3% |
| Return on equity | 5.0% |
| Net Margin | 11.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?
Apr 04
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today
Mar 08Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jan 31Is Synmosa Biopharma (GTSM:4114) A Risky Investment?
Jan 05Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09
Revenue & Expenses BreakdownBeta
How Synmosa Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5,140 | 595 | 1,292 | 211 |
| 30 Sep 23 | 5,059 | 585 | 1,283 | 211 |
| 30 Jun 23 | 4,931 | 562 | 1,278 | 202 |
| 31 Mar 23 | 4,677 | 800 | 1,229 | 216 |
| 31 Dec 22 | 4,386 | 799 | 1,151 | 215 |
| 30 Sep 22 | 4,048 | 735 | 1,078 | 206 |
| 30 Jun 22 | 3,721 | 693 | 982 | 222 |
| 31 Mar 22 | 3,441 | 368 | 923 | 216 |
| 31 Dec 21 | 3,235 | 304 | 884 | 214 |
| 30 Sep 21 | 3,141 | 288 | 857 | 204 |
| 30 Jun 21 | 3,105 | 293 | 844 | 185 |
| 31 Mar 21 | 3,012 | 634 | 837 | 172 |
| 31 Dec 20 | 3,038 | 638 | 826 | 160 |
| 30 Sep 20 | 2,931 | 582 | 800 | 172 |
| 30 Jun 20 | 2,861 | 519 | 794 | 189 |
| 31 Mar 20 | 2,849 | 95 | 795 | 198 |
| 31 Dec 19 | 2,680 | 47 | 789 | 212 |
| 30 Sep 19 | 2,579 | 40 | 798 | 207 |
| 30 Jun 19 | 2,486 | 61 | 803 | 198 |
| 31 Mar 19 | 2,384 | 73 | 807 | 191 |
| 31 Dec 18 | 2,363 | 431 | 826 | 184 |
| 30 Sep 18 | 2,249 | 432 | 789 | 193 |
| 30 Jun 18 | 2,119 | 409 | 758 | 216 |
| 31 Mar 18 | 2,017 | 379 | 703 | 202 |
| 31 Dec 17 | 1,861 | 5 | 646 | 188 |
| 30 Sep 17 | 1,795 | -34 | 652 | 183 |
| 30 Jun 17 | 1,772 | -38 | 645 | 142 |
| 31 Mar 17 | 1,821 | -6 | 673 | 149 |
| 31 Dec 16 | 1,865 | 165 | 711 | 146 |
| 30 Sep 16 | 1,894 | 173 | 731 | 134 |
| 30 Jun 16 | 1,926 | 180 | 734 | 137 |
| 31 Mar 16 | 1,856 | 180 | 710 | 132 |
| 31 Dec 15 | 1,776 | 32 | 671 | 131 |
| 30 Sep 15 | 1,706 | 58 | 649 | 138 |
| 30 Jun 15 | 1,644 | 75 | 635 | 140 |
| 31 Mar 15 | 1,562 | 97 | 624 | 150 |
| 31 Dec 14 | 1,476 | 110 | 602 | 140 |
| 30 Sep 14 | 1,423 | 122 | 568 | 125 |
| 30 Jun 14 | 1,329 | 107 | 528 | 113 |
| 31 Mar 14 | 1,275 | 91 | 496 | 96 |
| 31 Dec 13 | 1,249 | 63 | 474 | 94 |
| 30 Sep 13 | 1,207 | 50 | 456 | 88 |
| 30 Jun 13 | 1,177 | 53 | 445 | 87 |
Quality Earnings: 4114 has high quality earnings.
Growing Profit Margin: 4114's current net profit margins (11.6%) are lower than last year (18.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4114's earnings have grown significantly by 26.6% per year over the past 5 years.
Accelerating Growth: 4114's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4114 had negative earnings growth (-25.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4114's Return on Equity (5%) is considered low.